XNAS · Healthcare · Biotechnology
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -1.79 | -2.30 | -28.49% | $0 | ❌ Miss | -0.18% | -4.99% | — |
| 2026-02-24 | Q4 2025 | -1.49 | -1.80 | -20.81% | $0 | ❌ Miss | -3.73% | -2.49% | -10.82% |
| 2025-11-04 |
| Q3 2025 |
| -1.25 |
| -1.56 |
| -24.80% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -1.15 | -1.22 | -6.09% | $0 | ❌ Miss | -11.18% | -4.39% | +0.06% |
| 2025-05-07 | Q1 2025 | -0.92 | -1.04 | -13.04% | $0 | ❌ Miss | — | — | — |
| 2025-02-25 | Q4 2024 | -1.14 | -1.02 | +10.53% | $0 | ✅ Beat | — | — | — |
| 2024-11-05 | Q3 2024 | -1.11 | -0.83 | +25.23% | $0 | ✅ Beat | — | — | — |
| 2024-08-06 | Q2 2024 | -0.98 | -1.10 | -12.24% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.